Side-by-side comparison of AI visibility scores, market position, and capabilities
US MRI microstructure imaging algorithm (FDA-cleared July 2024) adding higher resolution to existing scanners projecting $2M additional annual revenue per scanner; YC $1.49M competing with Subtle Medical and Siemens AI-Rad Companion for radiology AI.
MICSI is a United States-based medical imaging technology company — backed by Y Combinator with $1.49 million raised from Graphene Ventures, NVO Capital, NYU Entrepreneurial Institute, Orange Collective, and Pioneer Fund — providing hospitals, radiology centers, and healthcare providers with the MICSI-RMT software (FDA-cleared July 2024), a Microstructure Imaging algorithm that analyzes standard MRI scanner data to generate higher-resolution tissue microstructure images and enable faster scan protocols, projecting $2 million in additional annual revenue per MRI scanner deployment for healthcare customers through improved diagnostic throughput and imaging quality. MICSI's technology works as a software overlay on existing MRI hardware — requiring no capital equipment purchase — making it deployable across the 35,000+ installed clinical MRI scanners in the United States.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.